MX2020000984A - Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. - Google Patents

Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.

Info

Publication number
MX2020000984A
MX2020000984A MX2020000984A MX2020000984A MX2020000984A MX 2020000984 A MX2020000984 A MX 2020000984A MX 2020000984 A MX2020000984 A MX 2020000984A MX 2020000984 A MX2020000984 A MX 2020000984A MX 2020000984 A MX2020000984 A MX 2020000984A
Authority
MX
Mexico
Prior art keywords
matrix
stable
protein kinase
kinase inhibitor
forming component
Prior art date
Application number
MX2020000984A
Other languages
English (en)
Inventor
Magnus Brisander
Mustafa Demirbüker
Gérald Jesson
Martin Malmsten
Helene Dérand
Original Assignee
Xpray Microparticles Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xpray Microparticles Ab filed Critical Xpray Microparticles Ab
Publication of MX2020000984A publication Critical patent/MX2020000984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Window Of Vehicle (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)

Abstract

La presente invención se refiere al campo de los métodos para proporcionar composiciones farmacéuticas que comprenden fármacos poco hidrosolubles. En particular, la presente invención se refiere a composiciones que comprenden nanopartículas híbridas amorfas estables que comprenden al menos un inhibidor de la proteína-cinasa y al menos un componente formador de la matriz y estabilizador polimérico, útiles en composiciones farmacéuticas y en terapia.
MX2020000984A 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. MX2020000984A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261586187P 2012-01-13 2012-01-13
SE1250015 2012-01-13
US201261713120P 2012-10-12 2012-10-12
SE1251160 2012-10-12

Publications (1)

Publication Number Publication Date
MX2020000984A true MX2020000984A (es) 2020-07-13

Family

ID=48781736

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014008457A MX347456B (es) 2012-01-13 2013-01-11 Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
MX2020000984A MX2020000984A (es) 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
MX2023008180A MX2023008180A (es) 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
MX2022003458A MX2022003458A (es) 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014008457A MX347456B (es) 2012-01-13 2013-01-11 Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2023008180A MX2023008180A (es) 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
MX2022003458A MX2022003458A (es) 2012-01-13 2014-07-10 Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.

Country Status (15)

Country Link
US (20) US9456992B2 (es)
EP (7) EP2802314B1 (es)
JP (13) JP6238311B2 (es)
CN (4) CN104159574A (es)
AU (8) AU2013208324B2 (es)
CA (2) CA2860973C (es)
DK (2) DK3181128T3 (es)
ES (2) ES2946735T3 (es)
FI (2) FI3181128T3 (es)
HR (2) HRP20230529T1 (es)
IL (4) IL293779B2 (es)
IN (1) IN2014DN06529A (es)
MX (4) MX347456B (es)
PL (3) PL3181122T3 (es)
WO (2) WO2013105894A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2802314T3 (da) * 2012-01-13 2021-01-25 Xspray Microparticles Ab Fremgangsmåde til fremstilling af stabile, amorfe hybride nanopartikler, der omfatter mindst én proteinkinaseinhibitor og mindst én polymer stabiliserende og matrixdannende bestanddel
CA2860973C (en) * 2012-01-13 2021-10-26 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
BR112015005940A2 (pt) 2012-09-17 2017-07-04 Bind Therapeutics Inc processo para a preparação de nanopartículas terapêuticas
CN104367557A (zh) * 2013-08-12 2015-02-25 浙江九洲药业股份有限公司 无定型药物活性成分与pvp组合物的制备方法
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
PL3116547T3 (pl) 2014-03-14 2019-11-29 Pfizer Terapeutyczne nanocząstki zawierające środek terapeutyczny i sposoby ich wytwarzania i zastosowania
WO2015145145A1 (en) * 2014-03-24 2015-10-01 Cipla Limited Pharmaceutical composition comprising lapatinib
WO2015145157A1 (en) * 2014-03-28 2015-10-01 Cipla Limited Pharmaceutical composition comprising pazopanib
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
MX2017001671A (es) * 2014-08-07 2017-07-04 Pharmacyclics Llc Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
WO2016090240A1 (en) * 2014-12-04 2016-06-09 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
WO2016097011A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous nilotinib
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
KR20180088274A (ko) * 2015-03-24 2018-08-03 다우 글로벌 테크놀로지스 엘엘씨 폴리머의 수용액
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
JP2019504027A (ja) 2015-12-22 2019-02-14 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 可溶性の生物製剤、治療薬、および造影剤を封入するためのプロセス
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
AU2017232868B2 (en) * 2016-03-17 2021-07-22 Sun Pharmaceutical Industries Ltd. Pharmaceutical composition of nilotinib
JP6739275B2 (ja) * 2016-08-02 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬組成物
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
CA3049926A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3056356A1 (en) 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Amorphous dispersion of cyclopropanecarboxylic acid (5-{5-[n'-(2- chloro-6-methylbenzoyl) hydrazinocarbonyl]-2-methyl-phenylethynyl}-pyridin-2-yl) amide
MA47793A (fr) * 2017-03-15 2020-01-22 Sun Pharma Advanced Res Co Ltd Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque
CN110461832A (zh) 2017-04-06 2019-11-15 庄信万丰股份有限公司 阿法替尼二马来酸盐的新形式
WO2018203636A1 (ko) * 2017-05-02 2018-11-08 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN107011262B (zh) * 2017-06-01 2019-10-29 中国药科大学 一种基于超临界抗溶剂技术制备甲苯磺酸索拉非尼多晶型k微粒的方法
WO2019055539A1 (en) * 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
KR101922369B1 (ko) * 2018-01-12 2018-11-26 한국지질자원연구원 경구 생체이용률 개선을 위한 약물-층상형 실리케이트 복합체, 이를 포함하는 경구용 약학 조성물 및 상기 복합체의 제조 방법
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
CN109833483B (zh) * 2018-09-17 2020-10-23 山东大学 基于小分子伴侣的索拉非尼纳米药物的制备
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
CN109044977A (zh) * 2018-10-26 2018-12-21 武汉工程大学 一种乐伐替尼固体分散体及其制备方法和制剂
WO2020093896A1 (en) * 2018-11-06 2020-05-14 Beijing Innocare Pharma Tech Co., Ltd. Amorphous solid dispersion comprising 6- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) nicotinamide
US10874671B2 (en) 2019-02-18 2020-12-29 Slayback Pharma Llc Pharmaceutical compositions of nilotinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
EP4093379A1 (en) 2020-01-24 2022-11-30 Nanocopoeia LLC Amorphous solid dispersions of dasatinib and uses thereof
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN111467501B (zh) * 2020-05-22 2021-06-15 深圳市泰力生物医药有限公司 具有改良溶出性质的组合物
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
AU2021314153A1 (en) 2020-07-23 2023-01-05 Crititech, Inc. Lapatinib particles and uses thereof
WO2022034914A1 (ja) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 易溶性固形製剤およびその製法
CN116234537A (zh) 2020-10-02 2023-06-06 隆萨本德公司 作为碱性药物的喷雾干燥中的加工助剂的醋酸
EP4032529A4 (en) * 2020-12-07 2022-11-16 Tianjin Creatron Biotechnology Co., Ltd. SORAFENIB PHARMACEUTICAL COMPOSITION WITH HIGH BIOAVAILABILITY AND USE THEREOF
EP4281047A1 (en) 2021-01-21 2023-11-29 XSpray Pharma AB (publ) Fast dissolving pharmaceutical compositions of dasatinib
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
CN115671110B (zh) * 2021-07-30 2024-05-10 上海云晟研新生物科技有限公司 帕唑帕尼口服药物组合物、其制备方法及应用
KR102686558B1 (ko) * 2022-01-25 2024-07-22 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제
WO2023155182A1 (zh) * 2022-02-21 2023-08-24 北京睿创康泰医药研究院有限公司 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用
WO2024080308A1 (ja) * 2022-10-12 2024-04-18 中外製薬株式会社 ペプチド、界面活性剤及びポリマーを含む組成物
KR20240115650A (ko) * 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법
CN116688139B (zh) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 一种克唑替尼药物组合物及其制备方法和应用
CN117100715B (zh) * 2023-09-05 2024-10-15 深圳市泰力生物医药有限公司 一种含无定型尼洛替尼的胶囊及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6406781B1 (en) * 1998-06-23 2002-06-18 3M Innovative Properties Company Stretch release adhesive article with stabilizer
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
GB9925934D0 (en) 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
SE0303476D0 (sv) 2003-12-22 2003-12-22 Censdelivery Ab Device, method and use for the formation of small particles
US7625911B2 (en) 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
CA2608952A1 (en) 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
DE102005053066A1 (de) * 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2007133750A2 (en) * 2006-05-12 2007-11-22 The Board Of Trustees Of The Leland Stanford Junior University Encapsulated nanoparticles for drug delivery
JP2009540010A (ja) * 2006-06-13 2009-11-19 エラン ファーマ インターナショナル，リミティド ナノ粒子状のキナーゼインヒビター製剤
CA2657379A1 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
JP2010509289A (ja) * 2006-11-09 2010-03-25 アボット ゲーエムベーハー ウント コンパニー カーゲー チロシンキナーゼ阻害剤の経口投与用薬学的剤形
CN101679356A (zh) 2007-04-05 2010-03-24 辉瑞产品公司 适用于治疗哺乳动物异常细胞生长的6-[2-（甲基-氨甲酰基）苯基硫基]-3-e-[2-(吡啶-2-基)乙烯基]吲唑的晶型
US7823700B2 (en) * 2007-07-20 2010-11-02 International Business Machines Corporation User identification enabled elevator control method and system
CN101918123B (zh) * 2007-12-07 2013-12-18 X喷雾微粒公司 生产微粒的方法与装置
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
US20090203709A1 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
GB0909154D0 (en) 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
CZ20098A3 (cs) 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
EP2579973A4 (en) * 2010-06-14 2017-01-18 Xspray Microparticles Ab Apparatus and method for the production of particles
AU2011303849A1 (en) * 2010-09-14 2013-04-04 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
CA2860973C (en) 2012-01-13 2021-10-26 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component.
JP2017141910A (ja) * 2016-02-10 2017-08-17 武蔵精密工業株式会社 伝動装置
JP6688624B2 (ja) * 2016-02-11 2020-04-28 学校法人 名城大学 ガスタンク及びこのガスタンクを複数備えたガスの貯蔵供給設備
JP6767610B2 (ja) * 2016-02-12 2020-10-14 パナソニックＩｐマネジメント株式会社 断熱体とその製造方法

Also Published As

Publication number Publication date
US20140356443A1 (en) 2014-12-04
JP2017222695A (ja) 2017-12-21
PL3181128T3 (pl) 2023-07-31
IL293775B1 (en) 2023-01-01
JP2017222694A (ja) 2017-12-21
EP3181128A1 (en) 2017-06-21
MX2022003458A (es) 2022-06-02
US11376243B2 (en) 2022-07-05
US20160361313A1 (en) 2016-12-15
US20220168285A1 (en) 2022-06-02
EP3766486A1 (en) 2021-01-20
MX2023008180A (es) 2023-08-03
AU2018200933B2 (en) 2020-01-02
JP7391507B2 (ja) 2023-12-05
AU2018200928B2 (en) 2019-07-18
CN107115318A (zh) 2017-09-01
IL293779A (en) 2022-08-01
ES2946549T3 (es) 2023-07-20
JP2019070000A (ja) 2019-05-09
US20190275018A1 (en) 2019-09-12
US10561643B2 (en) 2020-02-18
CN104159574A (zh) 2014-11-19
US9833442B2 (en) 2017-12-05
EP3181127B1 (en) 2023-03-08
MX347456B (es) 2017-04-27
AU2021269331A1 (en) 2021-12-09
US20170143683A1 (en) 2017-05-25
US9833443B2 (en) 2017-12-05
DK3181128T3 (da) 2023-06-06
JP6238311B2 (ja) 2017-11-29
JP2018012714A (ja) 2018-01-25
JP2018035147A (ja) 2018-03-08
JP6463418B2 (ja) 2019-02-06
CN104159577B (zh) 2017-03-15
AU2013208324B2 (en) 2017-11-23
US10772877B2 (en) 2020-09-15
US10555937B2 (en) 2020-02-11
IL293775A (en) 2022-08-01
US20180042906A1 (en) 2018-02-15
US20220117947A1 (en) 2022-04-21
CA2860932A1 (en) 2013-07-18
JP6628834B2 (ja) 2020-01-15
AU2018200928A1 (en) 2018-03-01
JP6351809B2 (ja) 2018-07-04
IL293779B1 (en) 2023-05-01
JP2021073228A (ja) 2021-05-13
AU2021269328A1 (en) 2021-12-09
US12076314B2 (en) 2024-09-03
US10314830B2 (en) 2019-06-11
FI3181122T3 (fi) 2023-05-31
EP3181127A1 (en) 2017-06-21
WO2013105895A1 (en) 2013-07-18
EP2802316A1 (en) 2014-11-19
AU2018200931B2 (en) 2019-07-18
CA2860932C (en) 2021-02-16
JP2015503612A (ja) 2015-02-02
US20160250153A1 (en) 2016-09-01
US20170143715A1 (en) 2017-05-25
DK3181122T3 (da) 2023-06-06
IL233583B (en) 2020-10-29
JP2015503613A (ja) 2015-02-02
AU2021269328B2 (en) 2024-07-25
AU2013208323A1 (en) 2014-07-24
JP2018172393A (ja) 2018-11-08
EP2802316A4 (en) 2015-11-18
JP2017222693A (ja) 2017-12-21
EP2802314B1 (en) 2020-11-25
MX2014008457A (es) 2015-02-12
US10561644B2 (en) 2020-02-18
EP4218740A1 (en) 2023-08-02
IL233582A0 (en) 2014-08-31
US11241419B2 (en) 2022-02-08
AU2021269331B2 (en) 2024-07-25
US20220296575A1 (en) 2022-09-22
US20190076413A1 (en) 2019-03-14
US11517562B2 (en) 2022-12-06
US20190275019A1 (en) 2019-09-12
JP6463419B2 (ja) 2019-02-06
JP6463416B2 (ja) 2019-02-06
AU2018200933A1 (en) 2018-03-01
IL293775B2 (en) 2023-05-01
US10314829B2 (en) 2019-06-11
EP3181128B1 (en) 2023-03-08
IL233583A0 (en) 2014-08-31
US20190255029A1 (en) 2019-08-22
US20190060294A1 (en) 2019-02-28
US20140378454A1 (en) 2014-12-25
PL3181122T3 (pl) 2023-07-31
FI3181128T3 (fi) 2023-06-02
EP3181122A1 (en) 2017-06-21
IL233582B (en) 2021-09-30
CN107115317A (zh) 2017-09-01
IN2014DN06529A (es) 2015-06-12
EP2802314A4 (en) 2015-08-12
AU2013208324A1 (en) 2014-07-24
HRP20230529T1 (hr) 2023-09-15
US11963951B2 (en) 2024-04-23
JP6463417B2 (ja) 2019-02-06
US10561645B2 (en) 2020-02-18
US9456992B2 (en) 2016-10-04
EP3181122B1 (en) 2023-03-08
WO2013105894A1 (en) 2013-07-18
PL2802314T3 (pl) 2021-06-14
IL293779B2 (en) 2023-09-01
EP2802314A1 (en) 2014-11-19
AU2018200931A1 (en) 2018-03-01
JP6351811B2 (ja) 2018-07-04
JP2018008973A (ja) 2018-01-18
ES2946735T3 (es) 2023-07-25
AU2019275513B2 (en) 2022-03-10
CA2860973C (en) 2021-10-26
AU2019275513A1 (en) 2019-12-19
US9827230B2 (en) 2017-11-28
CN104159577A (zh) 2014-11-19
HRP20230510T1 (hr) 2023-10-27
US20210093616A1 (en) 2021-04-01
CA2860973A1 (en) 2013-07-18
US20190282553A1 (en) 2019-09-19
US11426391B2 (en) 2022-08-30
US20220160687A1 (en) 2022-05-26
JP2018012713A (ja) 2018-01-25
JP6238310B2 (ja) 2017-11-29
JP2023123773A (ja) 2023-09-05
US20240189290A1 (en) 2024-06-13
US10143683B2 (en) 2018-12-04
US20200253941A1 (en) 2020-08-13
JP6351810B2 (ja) 2018-07-04
AU2013208323B2 (en) 2017-07-06
JP7006995B2 (ja) 2022-01-24

Similar Documents

Publication Publication Date Title
MX2022003458A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
EP3216448B8 (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2015000337A (es) Formulaciones de etanercept que exhiben reduccion notable en particulas subvisibles.
HK1206268A1 (en) Non linear multiblock copolymer drug conjugates for the delivery of active agents
WO2011139348A3 (en) Uses of phospholipid conjugates of synthetic tlr7 agonists
IN2014KN01664A (es)
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
GB201106750D0 (en) Novel compounds
PH12015501096A1 (en) Composition for immediate and extended release
EP3072506A4 (en) Carrier for drug delivery and conjugate, composition containing same, and method for administering same
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
WO2012068441A3 (en) Intedanib salts and solid state forms thereof
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
IL285017B (en) A pharmaceutical preparation containing stable amorphous hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component
CY1121238T1 (el) Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων
WO2014043252A3 (en) Hydroxypyridinone-,hydroxypyrimidinone-and hydroxypyridazinone drivatives and their therapeutic application
IL228666A0 (en) Pharmaceutical preparations for the prevention of HIV disease in humans and/or for its treatment
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
MX363558B (es) Composiciones farmaceuticas que comprenden flurbiprofeno.
IN2012DE00826A (es)
UA55891U (ru) Диаминосодержащие полиуретанмочевины с фолиевой кислотой как полимерные пленкообразующие биологически-активные материалы медицинского назначения
UA103450C2 (ru) Фолат-конъюгированный ферроцен как биологически активное соединение медицинского назначения
ZA201307390B (en) Pharmaceutical compositions for preventing and/or treating an hiv disease in humans